drugset / Trial / NCT03083470
Study of SOR007 Ointment for Actinic Keratosis
RandomizedSequentialTriple-blindTreatment
Summary
A Phase 2, randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (SOR007) compared to SOR007 ointment vehicle applied to actinic keratosis (AK) lesions on the face twice daily for up to 28 days.
Timeline
- Start
- 2017-05-18
- Primary completion
- 2018-03-12
- Completion
- 2018-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 0.15 % | Topical |
| Subject | Paclitaxel | Small molecule | 0.3 % | Topical |
| Subject | Paclitaxel | Small molecule | 1 % | Topical |
| Subject | Paclitaxel | Small molecule | 2 % | Topical |